CyanVac starts Phase 1 clinical trial for intranasal COVID-19 vaccine

CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., have enrolled the first participant in a Phase 1 clinical trial of their intranasal COVID-19 vaccine in Rochester, NY.